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Key messages
What is the key question?
 ► Whether switching from continuous (automatic) 
positive airway pressure (CPAP/APAP) to bilevel PAP 
would be clinically beneficial in patients for whom 
initial therapy was deemed ineffective.
What is the bottom line?
 ► A switch to bilevel was associated with clinically and 
statistically significant improvements in PAP therapy 
adherence.
Why read on?
 ► There are few data showing the benefits of bilevel 
PAP over standard CPAP/APAP in patients with ob-
structive sleep apnoea who are pressure intolerant.
AbstrAct
Introduction For patients with obstructive sleep apnoea 
(OSA) who are initially non-compliant with continuous 
(automatic) positive airway pressure (CPAP/APAP) therapy, 
a bilevel PAP (Spont/VAuto) therapy transition pathway is 
available to improve therapy adherence. The aim of this 
retrospective study was to compare PAP therapy usage 
data of patients with non-compliant OSA (ncOSA) on CPAP/
APAP who were switched to bilevel PAP.
Methods A PAP telemonitoring database was queried 
between 1 January 2015 and 31 July 2016 for eligible 
patients started on CPAP/APAP and non-CMS (United 
States Center for Medicare and Medicaid Services) 
compliant and switched to bilevel PAP within 90 days 
of starting CPAP/APAP therapy. PAP therapy data on all 
patients were compared before switch (CPAP/APAP) and 
after switch (VAuto/Spont).
results Of the 1496 patients with ncOSA identified, 
30.3% used CPAP, 62.3% APAP, and 7.4% both APAP and 
CPAP before switching to a bilevel mode. 47.8% patients 
switched to Spont mode and 52.2% to VAuto mode. PAP 
usage significantly improved by 0.9 h/day (p<0.001) and 
all other device metrics (residual apnoea–hypopnoea 
index and unintentional mask leak) also improved after 
the switch. No patients had achieved US CMS criteria for 
compliance before the switch, and 56.8% did after.
conclusion This shows for the first time that there may 
be potential benefit from switching from CPAP/APAP to 
bilevel PAP for patients struggling with PAP adherence.
Nasal continuous positive airway pressure 
(CPAP) is a highly efficacious therapy for 
obstructive sleep apnoea (OSA). However, 
poor adherence to therapy can limit the 
effectiveness of treatment.1 Efforts to improve 
adherence to positive airway pressure (PAP) 
therapy are a key issue in OSA management. 
These include intensive support,2 changes 
in interface, nasal decongestion, cognitive–
behavioural therapy and patient engagement 
techniques.3 Another option is to change the 
type of PAP mode, although existing data 
from observational studies and meta-anal-
ysis do not generally support the strategy 
of changing from one mode to another.4–8 
However, current evidence is flawed by unse-
lected populations and/or small numbers. 
Our clinical experience suggests that patients 
who are pressure intolerant sometimes have a 
preference for use of either expiratory pres-
sure relief or bilevel PAP modes in which a 
different pressure is provided during inspi-
ration versus expiration. However, finan-
cial considerations can lead to questions 
regarding the value of switching patients to a 
more expensive device.
To our knowledge, there are few data 
showing the benefits of bilevel PAP over 
standard CPAP/automatic CPAP (APAP) in 
patients with OSA who are pressure intol-
erant. Therefore, we retrospectively investi-
gated whether switching from CPAP/APAP to 
bilevel PAP would be clinically beneficial in 
patients for whom initial therapy was deemed 
ineffective. We used a big data approach in 
which records from individuals who had 
agreed to have their therapy device data 
stored using cloud-based technology were 
queried for potential changes in adherence.
We queried the AirView (ResMed) data-
base for patients who were initiated on 
CPAP or APAP and switched to a bilevel PAP 
(VAuto or Spont mode) within the first 90 
days after therapy initiation. The following 
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Figure 1 US Center for Medicare and Medicaid Services 
(CMS) bilevel reimbursement pathway. APAP, automatic 
continuous positive airway pressure; CPAP, continuous 
positive airway pressure; PAP, positive airway pressure.
device-derived parameters were determined before the 
switch (CPAP/APAP) and after the change to bilevel 
PAP: percentage of days with average daily PAP usage 
of ≥4 hours; average daily PAP usage; residual apnoea–
hypopnoea index (as a measure of therapy effective-
ness); leak; average PAP usage per session; percentage 
of patients achieving United States Center for Medicare 
and Medicaid Services (CMS) compliance criteria after 
switching to bilevel PAP therapy (CMS compliance is 
defined as device usage for ≥4 hours/night on 70% of 
nights in a consecutive 30-day period). These criteria 
are important because they need to be met for a health 
insurance provider to continue paying for the treatment 
device. Essentially, if a patient does not meet CMS criteria 
for insurance coverage, they will lose their PAP device. 
Patients had not reached the definition of CMS compli-
ance before the switch so that we could measure how 
many did then qualify after the switch.
Between 1 January 2015 and 31 July 2016, a total of 
1496 eligible patients (mean age 58.1±14.2 years) were 
identified from approximately 1.36 million patients; 
initial therapy was APAP in 62.3%, CPAP in 30.3%, and 
APAP and CPAP in 7.4%. The pathway for CMS reim-
bursement of bilevel PAP after switching from APAP or 
CPAP is shown in figure 1. After switching, the bilevel 
PAP mode was VAuto in 52.2% of patients and Spont 
in 47.8%. Average 95th percentile pressure before the 
switch (CPAP/APAP) was 12.5±3.7 cmH2O; after the 
switch to bilevel, average 95th percentile inspiratory and 
expiratory positive airway pressures were 15.1±4.1 and 
10.5±3.9 cmH2O, respectively. Switching to bilevel was 
associated with significant improvements in compliance 
and device metrics (table 1), regardless of bilevel PAP 
mode. Median average daily PAP usage improved by 0.9 
h/day (figure 2). The greatest improvement was seen in 
those with the lowest average 95th percentile pressure 
(range 4–10 cmH2O) with CPAP/APAP with an increase 
of 1.8 h/day, then the 10–15 cmH2O range with 0.8 h/
day increase followed by the 15–20 cmH2O range with 
0.7 h/day increase. Overall, 56.8% of patients who were 
non-compliant with CPAP/APAP achieved CMS compli-
ance criteria after switching to bilevel PAP; the propor-
tion of patients who achieved CMS criteria was 58.5% 
in the subgroup of patients switched by day 60 (59.9% 
of the total population) and 54.2% in the subgroup 
switched between day 61 and day 90 (40.1% of the total 
population).
These findings are the first to show that there may be 
potential benefit from switching to bilevel therapy from 
CPAP or APAP for patients who are struggling with PAP 
adherence. To the best of our knowledge, most prior 
studies in this area were small and based on determi-
nation of non-inferiority rather than superiority. The 
majority of existing literature has suggested that bilevel 
therapy is equivalent to CPAP. We know of only one small 
study that showed potential superiority with bilevel PAP 
therapy.9 However, it focused on a proprietary technology 
and the study was small and showed only modest benefits.
In our study, a switch to bilevel was associated with clin-
ically and statistically significant improvements in PAP 
therapy adherence with greatest improvements seen in 
those on lower pressures and those switched before day 
60. The study was specifically designed around the US 
CMS PAP adherence criteria, which require ongoing use 
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Table 1 Changes in compliance and device metrics
Before switch (CPAP/APAP) After switch (bilevel PAP) Difference P value
Average AHI 4.9 (2.0, 11.8) 4.0 (1.7, 9.2) –0.9 <0.001
Average median leak, L/min 5.0 (1.3, 11.3) 4.1 (1.1, 10.4) –0.9 <0.001
% Days with usage of ≥4 hours 52.7 (14.3, 86.9) 68.9 (27.8, 93.3) +16.2 <0.001
Values are median (IQR).
AHI, apnoea–hypopnoea index; APAP, automatic continuous positive airway pressure; CPAP, continuous positive airway pressure; PAP, 
positive airway pressure.
Figure 2 Median average daily positive airway pressure 
device usage. APAP, automatic continuous positive airway 
pressure; CPAP, continuous positive airway pressure; PAP, 
positive airway pressure.
of PAP therapy for patients to keep the equipment. The 
goal was to identify strategies that could impact clinical 
care under current reimbursement pathways. As such, 
the observed improvement in adherence to therapy asso-
ciated with a switch to bilevel PAP could allow a substan-
tial proportion of patients (up to 57% in this study) who 
would otherwise not have met CMS criteria to keep their 
funded PAP device rather than have to discontinue or 
pay for therapy. Thus, there are clear benefits to patients 
who improve adherence in this context. Achieving CMS 
criteria means that patients are able to retain their funded 
PAP therapy and continue to benefit from treatment. If 
CMS criteria are not met and the patient does not choose 
to pay for therapy, they would have to go through the 
complete clinical pathway of physician consultation, sleep 
study, diagnosis and therapy initiation if they wanted to 
try again to access funded CPAP therapy.
Although our study had a number of strengths, we also 
acknowledge some limitations. It was not a randomised 
trial and therefore we cannot rule out the possibility that 
patients who switched to bilevel PAP were systematically 
different from those who did not. In addition, we cannot 
exclude the possibility that other adherence-improving 
measures were implemented at the time of the switch to 
bilevel PAP nor do we know the mechanisms of the benefit. 
In theory, frequent visits to a healthcare provider could have 
intangible benefits to patients that may be as important as 
the change in PAP technology. Given that patients were 
selected based on poor compliance, regression to the mean 
could also contribute to some of the improvements in 
compliance seen in our study. However, early device usage 
tends to predict longer-term usage, so the contribution of 
regression to the mean to the increase in device usage seen 
in our analysis may be small. Based on our study design 
and the nature of the de-identified database queried, we 
do not know specific details about our participants and 
cannot determine whether the observed benefits vary by 
factors such as age, race, gender or socioeconomic status. 
Thus, further research is also recommended in this area. 
Finally, we did not have the ability to assess major outcomes 
and therefore do not know whether the change to bilevel 
therapy had any beneficial effects on OSA-related symptoms 
or comorbidities. However, improvements in PAP device 
usage of at least 0.5 h/day have been defined as being clin-
ically relevant.9 Therefore, the 0.9 h/day improvement in 
device usage after a switch to bilevel PAP therapy in our 
study is considered likely to be associated with some bene-
fits for patients.
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